New thiazolidinediones affect endothelial cell activation and angiogenesis
- 1 July 2016
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 782, 98-106
Abstract
No abstract availableKeywords
Funding Information
- São Paulo Research Foundation (2012/51316-5)
- CNPq (573663/2008-4, BFU2011-2476, 151568/2013-8)
- FAPESP (2011/24020-5, 2009/53072-3)
This publication has 40 references indexed in Scilit:
- Thiazolidinediones and PPARγ agonists: time for a reassessmentTrends in Endocrinology & Metabolism, 2012
- Diabetic RetinopathyNew England Journal of Medicine, 2012
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesisAngiogenesis, 2008
- Selective Activation of Peroxisome Proliferator–Activated Receptor (PPAR)α and PPARγ Induces Neoangiogenesis Through a Vascular Endothelial Growth Factor–Dependent MechanismDiabetes, 2008
- The Role of PPARs in the Endothelium: Implications for Cancer TherapyPPAR Research, 2008
- Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent MechanismArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Neuropathic Diabetic Foot UlcersNew England Journal of Medicine, 2004
- Peroxisome Proliferator-Activated Receptor γ Ligands Increase Release of Nitric Oxide From Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- The Mechanism by which 4-Hydroxy-2,2,6,6-tetramethylpiperidene-1-oxyl (Tempol) Diverts Peroxynitrite Decomposition from Nitrating to Nitrosating SpeciesChemical Research in Toxicology, 2002